Home > Analytics > SYNCOM FORMULATIONS (INDIA)

SYNCOM FORMULATIONS (INDIA)
Intrinsic Value | Fundamental Analysis

BOM : 524470     NSE :     
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward
Pledged Shares : None or < 25%
Aug 10,2022
Price(EOD): ₹ 9.32
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 876.08 Cr
Value of ₹ 1 Lac invested in SYNCOM FORMULATIONS (INDIA)
on Aug 10,2017 (price: ₹ 1.46)

₹ 1 L

₹ 6.38 L

1W : 2.3% 1M : 16.4% 1Y : 26.3%
COMMUNITY POLL
for SYNCOM FORMULATIONS (INDIA)
Please provide your vote to see the results
SYNCOM FORMULATIONS (INDIA) is part of below Screeners ↓
Best 1M Momentum Small Cap Stocks
Industry Peers & Returns1W1M1Y
SYNCOM FORMULATIONS (INDIA) 2.3% 16.4% 26.3%
SUN PHARMACEUTICAL INDUSTRIES 2.5% 7.3% 16%
DIVIS LABORATORIES 3.2% 5.7% -20.7%
DR REDDYS LABORATORIES 3.6% -5.8% -11.6%
CIPLA 2.7% 9.7% 13%
GLAND PHARMA 1.9% -7.6% -41.8%
PIRAMAL ENTERPRISES 4% 3.3% -32.8%
CADILA HEALTHCARE 5.3% -1.6% -38.5%
TORRENT PHARMACEUTICALS 1.8% 4% 1.7%

FUNDAMENTAL ANALYSIS OF SYNCOM FORMULATIONS (INDIA)

 
Fundamentals Score
[ Q(TTM): Mar2022, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SYNCOM FORMULATIONS (INDIA)

 
Valuation Score
[As on : Aug 10,2022 ]

Ratio Standalone
P/E
P/B
P/S
25.19
P/E Calculated based on EPS of 0.37
[ Mar2021 - Standalone Results ]

4.14
P/B Calculated based on Book Value of 2.25
[ Mar2021 - Standalone Results ]

3.99
P/S Calculated based on Revenues of 219.663 Cr
[ TTM - Standalone Results ]

Financial Ratios →

Insights 💡 There are potential 18% undervalued companies ! Discover More →

FAIR VALUE OF SYNCOM FORMULATIONS (INDIA)

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
1194%
346%
401%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SYNCOM FORMULATIONS (INDIA)


Insights 💡 SYNCOM FORMULATIONS (INDIA) is one of the top 46% companies with bullish price momentum currently! Discover More →

SYNCOM FORMULATIONS (INDIA) vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SYNCOM FORMULATIONS (INDIA)

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0.35
0.01
0.07
0.14
-
-
-
-
[Last Annual Data : Mar2021]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SYNCOM FORMULATIONS (INDIA)

Pledged Promoter Shares
0 %
As on : Jun2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SYNCOM FORMULATIONS (INDIA)

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
1.76%
-61.33%
-5.14%
18.54%
-11.15%
-77.47%
-48.2%
-31.54%
QtrlyTrend
-4
Latest Qtr: Mar2022
Quarterly Result Analysis →


SYNCOM FORMULATIONS (INDIA) related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 1.1% 4.8% -12.1%
S&P BSE ALLCAP 0.8% 8.3% 7.3%
S&P BSE SMALL CAP 0.4% 7.9% 3.5%
S&P BSE MIDSMALLCAP 0.2% 8% 4.6%
No NSE index found

You may also like the below Video Courses


FAQ about SYNCOM FORMULATIONS (INDIA)


Is SYNCOM FORMULATIONS (INDIA) good for long term investment?

As on Aug 10,2022, the Fundamentals of SYNCOM FORMULATIONS (INDIA) look Poor and hence it may not be good for long term investment ! See Financial Performance of SYNCOM FORMULATIONS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SYNCOM FORMULATIONS (INDIA) UnderValued or OverValued?

As on Aug 10,2022, SYNCOM FORMULATIONS (INDIA) is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) ?

As on Aug 10,2022, the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) is Rs. 1.86 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 0.72
Fair Value [Median EV / Sales Model] : Rs. 2.09
Fair Value [Median Price / Sales Model] : Rs. 1.86
Median Fair Value of SYNCOM FORMULATIONS (INDIA) : Rs. 1.86

Is SYNCOM FORMULATIONS (INDIA) trading at a Premium or Discount?

As on Aug 10,2022, SYNCOM FORMULATIONS (INDIA) is trading at a Premium of 401% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].